In April 2018, we entered into an asset contribution agreement for Pfizer’s allogeneic CAR T (AlloCAR T™) cell therapy portfolio. We are advancing the portfolio acquired from Pfizer, which includes rights to 15 preclinical CAR T cell therapy targets licensed from Cellectis and U.S. rights to clinical candidates ALLO-501 and UCART19 licensed from Servier.
Allogene initiated its Phase 1 ALPHA study of ALLO-501 in the first half of 2019 to assess safety and tolerability of ALLO-501 and ALLO-647, our proprietary anti-CD52 monoclonal antibody, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). ALLO-501 is being developed under a joint clinical development collaboration with Servier and is exclusively licensed from Cellectis. ALLO-501 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. We have the exclusive rights to ALLO-501 in the U.S. while Servier retains exclusive rights for all other countries.
Through our R&D partnerships with Servier and Cellectis, we are leveraging our pioneering technology platform of AlloCAR T™ therapy, also known as AlloCARs™, enhanced by Cellectis’ TALEN® gene editing technology, to advance our portfolio of cancer therapies.
We have a joint clinical development collaboration with Servier for UCART19, which is being developed for the treatment of adult and pediatric acute lymphoblastic leukemia (ALL). It is exclusively licensed from Cellectis. UCART19 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. We have the exclusive rights to UCART19 in the U.S. while Servier retains exclusive rights for all other countries.
We assumed from Pfizer its strategic collaboration and license agreement with Cellectis, with exclusive rights to develop and commercialize previously defined allogeneic CAR T therapy programs directed at select targets. We believe this alliance with Cellectis will lead to a strong pipeline of AlloCAR T™ therapies.